Laboratory Follow-Up for Dengue Fever
Monitor complete blood count (CBC) with platelet count and hematocrit every 24–48 hours during the critical phase (days 3–7 of illness) to detect plasma leakage and thrombocytopenia, which are the primary indicators of progression to severe dengue requiring immediate intervention. 1
Initial Diagnostic Testing (Days 0–7)
Early Phase (Days 0–4 of Fever)
- RT-PCR is the preferred test with 95% sensitivity when collected within 0–4 days of symptom onset 2
- NS1 antigen ELISA shows comparable diagnostic accuracy to RT-PCR (90% sensitivity, 93% specificity) and is more accessible and cost-effective 2
- IgM ELISA is unreliable during days 0–3, with 0% detection in primary dengue; sensitivity improves to only 55% during days 4–7 3
- Viral isolation by mosquito inoculation remains positive through day 5 of fever but becomes less practical after this window 4
Late Acute Phase (Days 5–7)
- RT-PCR sensitivity persists through days 7–8, even after defervescence and in the presence of antibodies 4
- IgM ELISA becomes more reliable after day 7 (94% sensitivity in primary dengue, 78% in secondary dengue) 3
- Both dengue and Zika IgM should be performed due to cross-reactivity, with positive results requiring confirmatory PRNT 5
Critical Phase Monitoring (Days 3–7)
Hematologic Parameters
- Daily CBC with differential to track:
- Platelet count: Progressive thrombocytopenia signals plasma leakage
- Hematocrit: Rising hematocrit (≥20% increase) indicates hemoconcentration from vascular leak
- White blood cell count: Leukopenia is common but not prognostic 1
Clinical Correlation
- Laboratory monitoring must occur without waiting for diagnostic test results to prevent complications from plasma leakage and organ damage 1
- The critical phase typically occurs around defervescence when patients may appear to improve clinically despite worsening laboratory parameters 1
Convalescent Phase (After Day 7)
Serologic Confirmation
- IgM ELISA on specimens collected >7 days after onset reliably detects infection 5
- Paired serology (acute and convalescent samples 2–4 weeks apart) demonstrates seroconversion in primary dengue 3
- IgG titers are significantly higher in secondary versus primary infection, though overlap exists 3
Indeterminate Results Management
- Trace-positive IgM requires repeat testing on the same specimen or confirmatory PRNT 5
- PRNT interpretation:
Special Considerations
Secondary Dengue
- IgG antibodies present early in the acute phase distinguish secondary from primary infection 3
- IgM response is blunted: Only 47% positive during days 4–7 compared to 55% in primary infection 3
- Higher risk of severe disease due to antibody-dependent enhancement 6
Cross-Reactivity Pitfalls
- Flavivirus cross-reactivity (Zika, yellow fever, Japanese encephalitis) produces false-positive IgM results in endemic regions 5
- IgM persistence for months after infection limits timing determination; epidemiologic context is essential 5
- Prior vaccination impacts antibody test interpretation and may require algorithm modification 7
Pregnant Patients
- Same diagnostic algorithm applies but prolonged IgM persistence prevents precise timing of infection 5
- Both dengue and Zika testing is mandatory given overlapping teratogenic risks 1
- Clinical and epidemiologic factors must supplement serology to assess pregnancy-related exposure timing 1
Practical Algorithm
Days 0–4: Order RT-PCR or NS1 antigen + daily CBC with platelets and hematocrit 2, 4
Days 5–7: Continue RT-PCR if available + IgM ELISA (both dengue and Zika) + daily CBC monitoring 5, 4
After Day 7: IgM ELISA (both dengue and Zika) with PRNT for positive or indeterminate results + CBC as clinically indicated 5, 3
Throughout illness: Serial hematocrit and platelet monitoring every 24–48 hours during the critical phase regardless of diagnostic test availability 1